Vectus Biosystems Ltd
ASX:VBS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Vectus Biosystems Ltd
Common Stock
Vectus Biosystems Ltd
Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
V
|
Vectus Biosystems Ltd
ASX:VBS
|
Common Stock
AU$38.4m
|
CAGR 3-Years
1%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Mesoblast Ltd
ASX:MSB
|
Common Stock
$1.5B
|
CAGR 3-Years
8%
|
CAGR 5-Years
7%
|
CAGR 10-Years
7%
|
|
|
CSL Ltd
ASX:CSL
|
Common Stock
$206m
|
CAGR 3-Years
-65%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Race Oncology Ltd
ASX:RAC
|
Common Stock
AU$81.6m
|
CAGR 3-Years
10%
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Common Stock
AU$480m
|
CAGR 3-Years
9%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Common Stock
AU$369.6m
|
CAGR 3-Years
43%
|
CAGR 5-Years
24%
|
CAGR 10-Years
23%
|
|
Vectus Biosystems Ltd
Glance View
Vectus Biosystems Ltd. operates as a drug discovery and development company. The company is headquartered in Rosebery, New South Wales. The company went IPO on 2016-02-23. The firm has developed treatments for fibrosis and high blood pressure, which include treatment for four of the diseases in the fibrotic franchise, namely heart, kidney, liver and lung disease. Its lead compound VB0004, which is aimed at treating the loss of functional tissue to fibrosis or scarring and high blood pressure. The firm has also developed a technology, Accugen for measuring the amount of Deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) in samples tested in laboratories. Using its platform technology, the Company has constructed a library of approximately 200 small molecules with varying degrees of anti-hypertensive and anti-fibrotic properties. Accugen is developed by the Company's subsidiary, Accugen Pty Limited. Accugen comprises reagents and software that quantitate quantitative polymerase chain reaction (qPCR) reactions.
See Also
What is Vectus Biosystems Ltd's Common Stock?
Common Stock
38.4m
AUD
Based on the financial report for Dec 31, 2025, Vectus Biosystems Ltd's Common Stock amounts to 38.4m AUD.
What is Vectus Biosystems Ltd's Common Stock growth rate?
Common Stock CAGR 5Y
9%
Over the last year, the Common Stock growth was 0%. The average annual Common Stock growth rates for Vectus Biosystems Ltd have been 1% over the past three years , 9% over the past five years .
